Ireland - English - HPRA (Health Products Regulatory Authority)

aspire pharma limited - leflunomide - film-coated tablet - 10 milligram(s) - selective immunosuppressants; leflunomide

Ireland - English - HPRA (Health Products Regulatory Authority)

european regulatory affairs t/a ivowen - leflunomide - film-coated tablet - 10 milligram(s) - selective immunosuppressants; leflunomide

Ireland - English - HPRA (Health Products Regulatory Authority)

european regulatory affairs t/a ivowen - leflunomide - film-coated tablet - 20 milligram(s) - selective immunosuppressants; leflunomide

Ireland - English - HPRA (Health Products Regulatory Authority)

morningside healthcare (malta) limited - leflunomide - film-coated tablet - selective immunosuppressants; leflunomide

Ireland - English - HPRA (Health Products Regulatory Authority)

morningside healthcare (malta) limited - leflunomide - film-coated tablet - selective immunosuppressants; leflunomide

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - leflunomide -

United States - English - NLM (National Library of Medicine)

a-s medication solutions - leflunomide (unii: g162gk9u4w) (leflunomide - unii:g162gk9u4w) - leflunomide tablets are indicated for the treatment of adults with active rheumatoid arthritis (ra). leflunomide tablets are contraindicated in: - pregnant women. leflunomide tablets  may cause fetal harm. if a woman becomes pregnant while taking this drug, stop leflunomide tablets, apprise the patient of the potential hazard to the fetus, and begin a drug elimination procedure [see warnings and precautions (5.1 and 5.3) and use in specific populations (8.1)]. - patients with severe hepatic impairment [see warnings and precautions (5.2)]. - patients with known hypersensitivity to leflunomide or any of the other components of leflunomide tablets. known reactions include anaphylaxis [see adverse reactions (6.1)]. - patients being treated with teriflunomide [see drug interactions (7)]. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to leflunomide during pregnancy. health care providers and patients are encouraged to report pregnancies by calli

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - leflunomide, quantity: 20 mg - tablet, uncoated - excipient ingredients: magnesium stearate; crospovidone; lactose; colloidal anhydrous silica - terry white chemists leflunomide is indicated for the treatment of: active rheumatoid arthritis; active psoriatic arthritis. terry white chemists leflunomide is not indicated for the treatment of psoriasis that is not associated with manifestations of arthritic disease. the combined use of terry white chemists leflunomide with other disease modifying antirheumatic drugs (dmards) has not been adequately studied (see precautions).

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - leflunomide, quantity: 10 mg - tablet, uncoated - excipient ingredients: colloidal anhydrous silica; crospovidone; lactose; magnesium stearate - terry white chemists leflunomide is indicated for the treatment of: active rheumatoid arthritis; active psoriatic arthritis. terry white chemists leflunomide is not indicated for the treatment of psoriasis that is not associated with manifestations of arthritic disease. the combined use of terry white chemists leflunomide with other disease modifying antirheumatic drugs (dmards) has not been adequately studied (see precautions).

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - leflunomide -